Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Sell
14
NRC Quote, Financials, Valuation and Earnings
Last price:
$17.16
Seasonality move
:
-3.7%
Day range:
$16.82 - $17.88
52-week range:
$16.74 - $42.18
Dividend yield:
2.8%
P/E ratio:
15.19x
P/S ratio:
2.86x
P/B ratio:
11.64x
Volume:
333.3K
Avg. volume:
104.7K
1-year change:
-56.56%
Market cap:
$403.1M
Revenue:
$148.6M
EPS (TTM):
$1.13
Analysts' Opinion
-
Consensus RatingNational Research has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, National Research has an estimated downside of -- from its current price of $17.17.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $17.17.
Fair Value
-
According to the consensus of 0 analysts, National Research has -- downside to fair value with a price target of -- per share.
NRC vs. S&P 500
-
Over the past 5 trading days, National Research has underperformed the S&P 500 by -1.53% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
National Research does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
National Research revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter National Research reported revenues of $35.8M.
Earnings Growth
-
National Research earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter National Research reported earnings per share of $0.24.
Enterprise value:
453.3M
EV / Invested capital:
5.14x
Price / LTM sales:
2.86x
EV / EBIT:
12.11x
EV / Revenue:
3.14x
PEG ratio (5yr expected):
5.04x
EV / Free cash flow:
18.00x
Price / Operating cash flow:
16.39x
Enterprise value / EBITDA:
10.46x
Gross Profit (TTM):
$87.8M
Return On Assets:
22.04%
Net Income Margin (TTM):
18.79%
Return On Equity:
61.94%
Return On Invested Capital:
32.47%
Operating Margin:
22.28%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $151.7M | $148.7M | $144.2M | $37.9M | $35.8M | |
| Gross Profit | $94.5M | $92.5M | $87.8M | $23.3M | $20.5M | |
| Operating Income | $47.2M | $40.6M | $37.3M | $10M | $8M | |
| EBITDA | $52.4M | $44.7M | $43.4M | $11.8M | $9.5M | |
| Diluted EPS | $1.38 | $1.16 | $1.13 | $0.32 | $0.24 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $47.4M | $72.7M | $49.1M | $24.7M | $20.7M | |
| Total Assets | $127.2M | $156.2M | $135M | $120.1M | $131.8M | |
| Current Liabilities | $32.1M | $39.2M | $41.1M | $40.8M | $44.3M | |
| Total Liabilities | $70.5M | $73.1M | $67.2M | $62.3M | $97.2M | |
| Total Equity | $56.7M | $83.1M | $67.8M | $57.9M | $34.6M | |
| Total Debt | $31.6M | $27.6M | $23.3M | $23.8M | $53.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $40.2M | $34.5M | $40M | $9.8M | $9.4M | |
| Cash From Investing | -$9.6M | -$14M | -$19.6M | -$4.5M | -$6.4M | |
| Cash From Financing | -$54.5M | -$45.1M | -$20.7M | -$24M | -$17K | |
| Free Cash Flow | $30.6M | $20.5M | $25.2M | $5.3M | $7.8M | |
NRC
Sector
Market Cap
$403.1M
$44.6M
Price % of 52-Week High
40.71%
45.71%
Dividend Yield
2.8%
0%
Shareholder Yield
8.03%
-0.68%
1-Year Price Total Return
-56.57%
-29.09%
Beta (5-Year)
0.516
0.772
Dividend yield:
2.8%
Annualized payout:
$1.48
Payout ratio:
42.77%
Growth streak:
3 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$17.70
200-day SMA
Sell
Level
$25.58
Bollinger Bands (100)
Sell
Level
18.56 - 22.16
Chaikin Money Flow
Sell
Level
-1.3M
20-day SMA
Sell
Level
$18.74
Relative Strength Index (RSI14)
Sell
Level
35.82
ADX Line
Buy
Level
7.3
Williams %R
Buy
Level
-86.5415
50-day SMA
Sell
Level
$18.94
MACD (12, 26)
Sell
Level
-0.59
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
7.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.6721)
Buy
CA Score
(Annual)
Level (1.3528)
Buy
Beneish M-Score
(Annual)
Level (-2.9614)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.674)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
Stock Forecast FAQ
In the current month, NRC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NRC average analyst price target in the past 3 months is --.
-
Where Will National Research Stock Be In 1 Year?
According to analysts, the consensus estimate is that National Research share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About National Research?
Analysts are divided on their view about National Research share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that National Research is a Sell and believe this share price will rise from its current level to --.
-
What Is National Research's Price Target?
The price target for National Research over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NRC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for National Research is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NRC?
You can purchase shares of National Research via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase National Research shares.
-
What Is The National Research Share Price Today?
National Research was last trading at $17.16 per share. This represents the most recent stock quote for National Research. Yesterday, National Research closed at $17.17 per share.
-
How To Buy National Research Stock Online?
In order to purchase National Research stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Lucid vs Rivian Stock: Which Is Best?
Few realize that Lucid Group (NASDAQ: LCID) traces part of…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
